Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL GETZ

Allopathic & Osteopathic Physicians Dermatology

NPI
1508866443
CMS profile
249750
Location
WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$161.56

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $161.56 8

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL GETZ

NPI 1508866443 · CMS profile ID 249750

Allopathic & Osteopathic Physicians / Dermatology

WEST DUNDEE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). PAUL GETZ, NPI 1508866443, CMS profile ID 249750. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
PAUL GETZ, NPI 1508866443, CMS profile ID 249750, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1508866443?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $161.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $18.5712/12/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719348743 CMS
Regeneron Healthcare Solutions, Inc. $27.6911/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 724423547 CMS
Lilly USA, LLC $15.8510/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728587957 CMS
Janssen Biotech, Inc. $22.4609/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719348741 CMS
Lilly USA, LLC $23.7407/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728577909 CMS
Novartis Pharmaceuticals Corporation $14.1807/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725751795 CMS
Janssen Biotech, Inc. $15.0401/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719348739 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $24.0301/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 737461925 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,203.48 19
PY2020 $161.56 8
PY2021 $1,512.52 60
PY2022 $1,032.69 42
PY2023 $888.03 32
PY2024 $985.47 43
PY2025 $621.06 48

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,013.60 1
PY2025 Principal investigator $446,834.92 130
PY2024 Recipient $7,087.86 1
PY2024 Principal investigator $650,362.14 156
PY2023 Recipient $10,934.40 2
PY2023 Principal investigator $209,903.19 44
PY2022 Principal investigator $139,606.12 29
PY2021 Recipient $11,617.83 3
PY2021 Principal investigator $358,649.13 52
PY2020 Principal investigator $277,127.30 39
PY2019 Principal investigator $329,491.24 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

55 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $12,535.00 12/23/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830982977
Principal investigator 1 ABBVIE INC. $3,154.00 12/02/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792485465
Principal investigator 1 PFIZER INC. $3,270.80 11/20/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665301
Recipient Eli Lilly and Company $70.33 11/08/2021 Covered Recipient Physician A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819445815
Principal investigator 1 PFIZER INC. $170.30 11/04/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832663859
Principal investigator 1 PFIZER INC. $5,156.80 11/04/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665013
Principal investigator 1 Eli Lilly and Company $10,306.80 10/27/2021 Non-covered Recipient Entity
PAUL GETZ MD SC
A PHASE 3, 16-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL- GROUP STUDY TO ASSESS THE IMPACT OF LEBRIKIZUMAB ON VACCINE RESPONSES IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 819462735
Principal investigator 1 UCB SA $7,529.85 10/21/2021 Non-covered Recipient Entity
PAUL GETZ, M.D., S.C.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. No dispute reported 06/30/2026 844228059
Principal investigator 1 PFIZER INC. $2,890.00 10/08/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832663145
Principal investigator 1 PFIZER INC. $2,561.00 10/08/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832663155
Principal investigator 1 PFIZER INC. $3,311.10 09/24/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832663839
Principal investigator 1 PFIZER INC. $2,561.00 09/21/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665153
Principal investigator 1 Amgen Inc. $73,478.26 09/07/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830982981
Principal investigator 1 PFIZER INC. $7,800.00 09/03/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665421
Principal investigator 1 PFIZER INC. $9,373.75 09/03/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665903
Principal investigator 1 Amgen Inc. $402.06 08/26/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Interchangeability Study - ABP 654 No dispute reported 06/30/2026 830982979
Principal investigator 1 UCB SA $10,472.85 08/26/2021 Non-covered Recipient Entity
PAUL GETZ, M.D., S.C.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. No dispute reported 06/30/2026 844229151
Principal investigator 1 PFIZER INC. $373.75 08/21/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664971
Principal investigator 1 PFIZER INC. $5,122.00 08/05/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665295
Principal investigator 1 ABBVIE INC. $2,012.00 07/29/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792470953
Principal investigator 1 PFIZER INC. $7,624.50 07/20/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664979
Principal investigator 1 PFIZER INC. $3,181.10 07/20/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665003
Principal investigator 1 PFIZER INC. $5,850.00 07/08/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664807
Principal investigator 1 PFIZER INC. $4,699.50 07/08/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664987
Principal investigator 1 ABBVIE INC. $2,012.00 06/30/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792465895
Principal investigator 1 PFIZER INC. $585.00 06/22/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665913
Principal investigator 1 UCB SA $1,983.60 06/21/2021 Non-covered Recipient Entity
PAUL GETZ, M.D., S.C.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. No dispute reported 06/30/2026 844225163
Recipient E.R. Squibb & Sons, L.L.C. $3,650.00 06/14/2021 Covered Recipient Physician A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 819890433
Principal investigator 1 PFIZER INC. $8,678.20 06/04/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832662209
Principal investigator 1 Amgen Inc. $275.00 05/31/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 830984973
Principal investigator 1 ABBVIE INC. $4,024.00 05/27/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792461013
Principal investigator 1 PFIZER INC. $7,670.00 05/21/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832662189
Principal investigator 1 PFIZER INC. $6,102.50 05/21/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664823
Principal investigator 1 UCB SA $9,549.00 05/20/2021 Non-covered Recipient Entity
PAUL GETZ, M.D., S.C.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. No dispute reported 06/30/2026 844226265
Principal investigator 1 PFIZER INC. $2,500.00 05/13/2021 Non-covered Recipient Entity
Paul Getz MD SC dba Dundee Dermatology
A PHASE 2B RANDOMIZED DOUBLE BLIND VEHICLE CONTROLLED PARALLELGROUP DOSE RANGING STUDY TO ASSESS EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF PF06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 832662199
Principal investigator 1 PFIZER INC. $170.30 05/07/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832663165
Recipient E.R. Squibb & Sons, L.L.C. $7,897.50 05/03/2021 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819890439
Principal investigator 1 ABBVIE INC. $1,577.00 04/29/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792450873
Principal investigator 1 PFIZER INC. $5,135.00 04/21/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665923
Principal investigator 1 PFIZER INC. $1,602.90 04/08/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665145
Principal investigator 1 UCB SA $29,937.15 04/08/2021 Non-covered Recipient Entity
PAUL GETZ, M.D., S.C.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. No dispute reported 06/30/2026 844224203
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,786.53 04/06/2021 Non-covered Recipient Entity
PAUL GETZ MD SC DUNDEE DERMATOLOGY
A RANDOMIZED DOUBLE BLIND MULTI CENTER STUDY ASSESSING SHORT 16 WEEKS AND LONG TERM EFFICACY UP TO 1 YEAR SAFETY AND TOLERABILITY OF 2 SUBCUTANEOUS SECUKINUMAB DOSE REGIMENS IN ADULT PATIENTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA SUNSHINE No dispute reported 06/30/2026 800639655
Principal investigator 1 ABBVIE INC. $1,577.00 03/30/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792438961
Principal investigator 1 PFIZER INC. $170.30 03/23/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664997
Principal investigator 1 PFIZER INC. $5,135.00 03/23/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665307
Principal investigator 1 PFIZER INC. $14,533.90 03/05/2021 Non-covered Recipient Entity
Dundee Dermatology
ABROCITINIB EXPANDED ACCESS PROTOCOL FOR THE TREATMENT OF ADOLESCENTS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832663849
Principal investigator 1 ABBVIE INC. $3,154.00 03/02/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792430841
Principal investigator 1 PFIZER INC. $5,135.00 02/23/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832665135
Principal investigator 1 UCB SA $411.35 02/22/2021 Non-covered Recipient Entity
PAUL GETZ, M.D., S.C.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. No dispute reported 06/30/2026 844223057
Principal investigator 1 UCB SA $240.31 02/22/2021 Non-covered Recipient Entity
PAUL GETZ, M.D., S.C.
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS. No dispute reported 06/30/2026 844223551
Principal investigator 1 PFIZER INC. $4,810.00 02/04/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664017
Principal investigator 1 ABBVIE INC. $2,200.25 01/28/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) No dispute reported 06/30/2026 792417861
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,757.92 01/25/2021 Non-covered Recipient Entity
Dundee Dermatology
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 819893983
Principal investigator 1 Amgen Inc. $8,049.00 01/20/2021 Non-covered Recipient Entity
DUNDEE DERMATOLOGY
Phase 2b study of Tezepelumab in Atopic Dermatitis. No dispute reported 06/30/2026 830984971
Principal investigator 1 PFIZER INC. $18,050.50 01/08/2021 Non-covered Recipient Entity
Dundee Dermatology
A PHASE 3B RANDOMIZED DOUBLEBLIND DOUBLEDUMMY ACTIVE CONTROLLED MULTICENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF ABROCITINIB COMPARED WITH DUPILUMAB IN ADULT PARTICIPANTS ON BACKGROUND TOPICAL THERAPY WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 832664815